By Catherine Eckford (European Pharmaceutical Review)2024-03-26T15:43:26
Phase III data shows that mRNA-1283 has a similar safety profile to Moderna's approved COVID-19 vaccines, the company states.
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-04-14T12:32:00Z
Sponsored by Thermo Fisher Scientific
2026-04-30T10:37:00
Sponsored by Shimadzu
2026-03-27T15:37:00
Sponsored by IMA Pharma
2025-05-19T09:58:00
Sponsored by bioMérieux, Entegris and Cencora, By European Pharmaceutical Review
2026-06-10T15:00:00 2026-06-10T16:00:00
Sponsored by BioDuro
2026-05-27T13:00:00 2026-05-27T14:00:00
Sponsored by TA Instruments
2025-05-30T09:22:00
Sponsored by Lonza QC Testing Solutions
Site powered by Webvision Cloud